Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor.
Adasme MF, Parisi D, Van Belle K, Salentin S, Haupt VJ, Jennings GS, Heinrich JC, Herman J, Sprangers B, Louat T, Moreau Y, Schroeder M.
Adasme MF, et al. Among authors: van belle k.
PLoS One. 2020 May 27;15(5):e0233089. doi: 10.1371/journal.pone.0233089. eCollection 2020.
PLoS One. 2020.
PMID: 32459810
Free PMC article.